RECORD 3, 2014 trial summary

A randomised clinical trial investigating the effect of everolimus versus sunitinib in patients with metastatic renal cell carcinoma

Studied treatment	everolimus
Control treatment	sunitinib

Patients	patients with metastatic renal cell carcinoma
Group sizes	238 / 233
treatment line	line 1

Blindness		Inclusion period
Follow-up duration		Centers
Lost to FU		geographical localisation
Primary endpoint		Design	Cross over
Hypothese	Non inferiority

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765-72 [PMID: 25049330] link to pdf add to Mendeley

ClinicalTrial.gov record NCT00903175

Registering number	NCT00903175 (see trial on clinicaltrials.gov)
Code Name

RECORD 3, 2014 trial summary PDF trial summary